Mr. Hombach is the Chair of the Audit Committee at Embecta (NASDAQ: EMBC), a global diabetes care company spun out of Becton Dickinson, and has held previous board positions at several other ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that ...

PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company ...

Mr. Hombach is the Chair of the Audit Committee at Embecta (NASDAQ: EMBC), a global diabetes care company spun out of Becton Dickinson, and has held previous board positions at several other ...

Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The stock has a 50 day moving average of $233.08 and a two-hundred day moving average of $233.02.

Looking at the universe of stocks we cover at Dividend Channel, on 3/10/25, Evergy Inc (Symbol: EVRG), Viatris Inc (Symbol: VTRS), and Becton, Dickinson & Co (Symbol: BDX) will all trade ex ...

Embecta's compelling ~44% free cash flow yield offers a strong risk-reward despite headwinds from new insulin technologies and GLP-1 drugs. See more here.

On Tuesday, 11 March 2025, Becton Dickinson (NYSE: BDX) presented at the Barclays 27th Annual Global Healthcare Conference, outlining its strategic focus on separating its Life Sciences business ...